GammaDelta Therapeutics receives FDA clearance of IND application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy
FDA also granted orphan drug designation to GDX012 for the treatment of Acute Myeloid Leukaemia GammaDelta Therapeutics has received US FDA clearance for the Investigational New Drug (IND) application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies. The […]

